Glucotrack Raises $2 Million Through Discounted Convertible Notes and Warrants

Glucotrack (GCTK) raised $2M via senior secured convertible notes and warrants, with notes carrying 8% annual interest and maturing in 9 months. Dawson James Securities acted as placement agent for a 7% fee and warrants. The funds were raised through a private placement.

Original reporting
Published Oct 22, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 9:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Glucotrack Raises $2 Million Through Discounted Convertible Notes and Warrants — source image
Decision brief

The 30-second read

$GCTKBearishLow
01

Why it matters

The financing introduces new debt and potential equity dilution, which may weigh on the share price in the short term.

02

Market read

A primary disclosure of a small financing event for a micro‑cap, with limited broader market impact.

03

What to watch

The note's conversion price floor and potential equity upside if the stock rallies.

Relevance 4/10Novelty 3/10Timing: post‑market today

Background

Glucotrack is a micro‑cap company that filed an 8‑K reporting a $2 million convertible note and warrant issuance.

Company-level read

Ticker impact

$GCTKBearishMedium confidence
Context

Glucotrack disclosed a $2 million private placement of senior secured convertible notes and warrants, a new financing event for the company.

Expected impact

likely downward pressure as the market prices in dilution and new debt.

Evidence & confidence

Small‑cap financing at a discount typically signals cash‑flow needs and can trigger short‑term sell‑off.

Market effects

Minimal impact on the broader biotech/health‑tech sector.

Limited to investors tracking micro‑cap financing activity.

None

Counterpoint

If the capital raise funds a breakthrough product, the dilution could be offset by future upside.

Key entities

  • Glucotrack, Inc.

    Issuer of the convertible notes and warrants.

  • Dawson James Securities

    Placement agent receiving a 7% cash fee.

Related articles

$GCTKHigh

On July 14, 2026, Glucotrack, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Glucotrack Merger Sub, Inc., a Nevada…

Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Other Events. Exhibit 99.1 unaudited pro forma financial information On July 14, 2026 (the “Closing Date”), Glucotrack, Inc., a Delaware corporation (“Glucotrack”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Glucotrack Merger Sub, Inc., a Nevada corporation (“Me

$GCTKMed

GCTK Stock Jumps As Qare Data Platform Launch Fuels Momentum

GlucoTrack Inc. (GCTK) stock surged 14.04% on October 28, 2026, driven by the launch of its Qare data platform. The company's stock has seen significant volatility, trading at $1.95 after a 380% increase from its low. GlucoTrack reported a quarterly net loss of $3.8M and negative free cash flow. The Qare platform, focused on GLP-1 medications, aims to collect and compare patient data, potentially attracting partnerships. The company also expanded its ai² platform globally.

$GCTKMed

Lōkahi plans one shot per visit instead of 15 for honeybee-venom treatment

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

$GLUCMed

Glucotrack Secures $5.5 Million Financing to Support Growth Strategy and Product Development

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.